Thirty-three actor types with possibilities to contribute to the reduction of antibiotic emissions from manufacturing. For each actor type, examples of their interests, possible actions and incentives and disincentives for those actions are listed (more details to be found in the main text and the supplementary material). Broadly common interests among actors, e.g. individual's/ employees desire to contribute to positive societal change (reducing pollution, improving public health) are implicit but have not been listed for each actor. For actors #15,16,17, 21 -Motivate #3: demand good pollution control for the API's they buy; -Monitor & reduce their own discharges; -Set internal discharge limits; -Act transparently with regards to production sites (also of suppliers) and environmental performance.
-Emission standards; -Legal requirements; -Economic incentives (price, costs, turnover); -Pressure from investors and buyers; -Reputation concerns.
-Transparency as a threat for reputation concerns; -Higher production cost; -Lack of follow-up of external demands -risks of unfair competition.
#2 Generic pharmaceutical companies -Increase turnover, reduce costs; -Strategic interests (e.g. "stay ahead of the curve"); -Preserve effectiveness of product by curbing antibiotic resistance.
-Motivate #3: demand good pollution control for the API's they buy; -Monitor & reduce their own discharges; -Set internal discharge limits; -Act transparently with regards to production sites (also of suppliers) and environmental performance.
-Emission standards; -Legal requirements; -Economic incentives (price, costs, turnover); -Pressure from investors and buyers.
-Higher production cost; -Lack of follow-up of external demands -risks of unfair competition;
# 3 Subcontracting pharmaceutical companies -Increase turnover, reduce costs; -Strategic interests (e.g. "stay ahead of the curve"); -Preserve effectiveness of product by curbing antibiotic resistance.
-Monitor and reduce their own discharges; -Set internal discharge limits; -Act transparently with regards to environmental performance.
-Emission standards; -Legal requirements; -Economic incentives (price, costs, turnover); -Pressure from investors and buyers (i.e. #1 & #2).
# 4 Umbrella organisations/ collaborations between pharmaceutical companies.
-Represent members (#1, #2, #3); -Align interests of members.
-Coordinate action -In addition to those applying to #1,2 and 3: become a stronger force for promoting common interests.
-Interest and priorities may differ between members.
#5 Owners of pharmaceutical companies -Profit on investment; -Reputation
concerns.
-(Threaten to) withdraw investments in #1, #2 and #3; -Power through representation in boards.
-Pressure from customers and interest groups; -Financial incentives (risk for loss of business associated with "scandals").
-Limits on (short-term) profits, as owners set profit expectations.
# 6 Waste water treatment plants (WWTPs) -Increase turnover, reduce costs.
-Implement more effective treatment; -Monitor and report emissions.
-Government legislation; -Subsidies.
-Costs.
# 7 Parallel importers -Increase turnover, reduce costs.
-Promote transparency and regulations.
-Pressure from buyers; -Legislation.
-Very limited ability to gain information on, or to influence the production chain # 8 Producing country states -Represent -Regulate industry in terms of -Political pressure from -Economic interests: protecting -Apply environmental criteria in procurement; -Improve awareness.
-Regulation.
-Pressure on cost-efficiency; -Limited negotiating power.
#21 Regional government (county council) and their regional medical products committees (Läkemedelskommittér)
-Represent population; -Protect public health; -Good, affordable health care; -Protect economic interests.
-Steer #20; -Weigh in environmental concerns in regional treatment recommendations.
-Political pressure by citizens and interest groups; -National policies; -Public health concerns. -Political pressure; -Treaties, multilateral agreements, foreign pressure.
-Non-aligning interests between member states; -Lobbying; -Lack of jurisdiction. Outside of e.g. EU.
#31 Agencies of multistate bodies (such as the European Medicines Agency)
-Follow statutes and directives as defined by #14.
-Amend licensing requirements (ERA) to include risks for AMR selection and production emissions; -Include environmental considerations in GMP; -facilitate transparency of production chains.
-Steering by #30.
-Lack of research data to define demands; -Lack of jurisdiction outside of e.g. EU.
#32 Media -Profit; -Credibility; -Public interest.
-Improve awareness; -Expose polluters; -Demand action from the majority of actors.
-More viewers/readers; -Curiosity; -Increased credibility.
-Opacity of productions chains; -Lack of emission data.
# 33 Scientific researchers and universities -Reputation; -Receive funding.
-Generate knowledge; -Educate and create awareness among other actors; -Propose scientifically funded actions for e.g. regulation and procurement.
-Curiosity -Reputation; -Funding;
-Institutional barriers to multidisciplinary and/or international cooperation; -Limited access to data and samples from industry.
